Initial Clinical Experience of MR-Guided Radiotherapy for Non-Small Cell Lung Cancer

• DOI: 10.3389/fonc.2021.617681
• Publication Date: 2021-03-10T06:42:26Z
• Authors: Cathryn B. Crockett; Pamela Samson; Robert Chuter; Michael Dubec; Corinne Faivre-Finn; Olga L. Green; Sara L. Hackett; Fiona McDonald; Clifford Robinson; Anna-Maria Shiarli; Michael W. Straza; Joost J. C. Verhoeff; Maria Werner-Wasik; Gregory Vlacich; David Cobben
• Keywords: Cancer Research; magnetic resonance imaging (MRI); Radiation Medicine; image-guided radiotherapy (IGRT); adaptive; 610; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; stereotactic body radiation therapy (SBRT); external beam radiotherapy; ResearchInstitutes_Networks_Beacons/mcrc; name=Manchester Cancer Research Centre; 3. Good health; non-small cell lung cancer (NSCLC); MR-guided radiotherapy (MRgRT); 03 medical and health sciences; 0302 clinical medicine; Oncology; Medicine and Health Sciences; Journal Article; RC254-282

Curative-intent radiotherapy plays an integral role in the treatment of lung cancer and therefore improving its therapeutic index is vital. MR guided radiotherapy (MRgRT) systems are the latest technological advance which may help with achieving this aim. The majority of MRgRT treatments delivered to date have been stereotactic body radiation therapy (SBRT) based and include the treatment of (ultra-) central tumors. However, there is a move to also implement MRgRT as curative-intent treatment for patients with inoperable locally advanced NSCLC. This paper presents the initial clinical experience of using the two commercially available systems to date: the ViewRay MRIdian and Elekta Unity. The challenges and potential solutions associated with MRgRT in lung cancer will also be highlighted.